New Two-Pronged attack on tough pancreatic cancer begins human testing
NCT ID NCT06217666
Summary
This early-stage study aims to find out if a new two-part treatment is safe for people with locally advanced pancreatic cancer. First, patients receive a precise, high-dose radiation treatment. Then, they receive an experimental immunotherapy drug (PCX12) injected directly into the tumor. The main goal is to check for side effects and determine the safest dose of PCX12 to use.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Rochester
Rochester, New York, 14642, United States
Contact
Conditions
Explore the condition pages connected to this study.